| Symbol | ABEO |
|---|---|
| Name | ABEONA THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1330 AVENUE OF THE AMERICAS,33RD FLOOR, NEW YORK, New York, 10019, United States |
| Telephone | +1 646 813-4701 |
| Fax | — |
| — | |
| Website | https://www.abeonatherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Additional info from NASDAQ: |
New Form PRE 14A - ABEONA THERAPEUTICS INC. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001493152-26-017879 <b>Size:</b> 3 MB
Read moreDirector Goldan Keith A. 🟢 acquired 32.8K shares of ABEONA THERAPEUTICS INC. (ABEO) Transaction Date: Apr 01, 2026 | Filing ID: 015456
Read more(50% Neutral) ABEONA THERAPEUTICS INC. (ABEO) Announces Regulatory Update
Read moreAbeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
Read moreAbeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
Read moreNew Form 3 - ABEONA THERAPEUTICS INC. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001493152-26-015453 <b>Size:</b> 28 KB
Read moreNew Form SCHEDULE 13G - ABEONA THERAPEUTICS INC. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0002073679-26-000044 <b>Size:</b> 102 KB
Read moreAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreAbeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05725018 | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in… | Phase3 | Epidermolysis Bullosa | Active_Not_Recruiting | 2023-04-02 | 2025-09-30 | ClinicalTrials.gov |
| NCT05708677 | A Long-Term Extension Study for Participants Previously Treated With EB-101 for… | — | RDEB | Enrolling_By_Invitation | 2021-02-09 | 2036-08-01 | ClinicalTrials.gov |
| NCT04655911 | A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101 | — | Mucopolysaccharidosis III-B | Terminated | 2020-10-28 | 2022-04-07 | ClinicalTrials.gov |
| NCT04227106 | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dys… | Phase3 | Epidermolysis Bullosa | Completed | 2020-01-10 | 2022-10-18 | ClinicalTrials.gov |
| NCT04088734 | Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of M… | Phase1 | MPS IIIA | Terminated | 2019-09-18 | 2022-03-10 | ClinicalTrials.gov |
| NCT03315182 | Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB | Phase1 | Mucopolysaccharidosis Type 3 B | Terminated | 2017-10-16 | 2022-04-07 | ClinicalTrials.gov |
| NCT02716246 | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH | Phase2 | MPS IIIA | Recruiting | 2016-04-25 | 2027-07-01 | ClinicalTrials.gov |
| NCT01263379 | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa | Phase1 | Epidermolysis Bullosa Dystrophica | Completed | 2010-10-05 | 2022-03-09 | ClinicalTrials.gov |
| NCT00385502 | A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infec… | Phase2 | Onychomycosis | Completed | 2006-09-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00563394 | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic U… | Phase3 | Diabetic Foot Ulcers | Completed | 1994-08-01 | 1996-07-01 | ClinicalTrials.gov |
| NCT00563433 | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic U… | Phase3 | Diabetic Foot Ulcers | Completed | 1994-08-01 | 1996-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EB-101 Surgical application of RDEB wounds | BIOLOGICAL | Phase PHASE3 | Epidermolysis Bullosa | ACTIVE_NOT_RECRUITING | NCT05725018 |
| ABO-101 | BIOLOGICAL | Preclinical | Mucopolysaccharidosis III-B | TERMINATED | NCT04655911 |
| EB-101 | BIOLOGICAL | Preclinical | RDEB | ENROLLING_BY_INVITATION | NCT05708677 |
| rAAV9.CMV.hNAGLU | BIOLOGICAL | Phase PHASE1 | Mucopolysaccharidosis Type 3 B | TERMINATED | NCT03315182 |
| MSI-78 | DRUG | Phase PHASE3 | Diabetic Foot Ulcers | COMPLETED | NCT00563433 |
| ofloxacin | DRUG | Phase PHASE3 | Diabetic Foot Ulcers | COMPLETED | NCT00563433 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | BIOLOGICAL | Phase PHASE1 | Epidermolysis Bullosa Dystrophica | COMPLETED | NCT01263379 |
| EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) | DRUG | Phase PHASE2 | Onychomycosis | COMPLETED | NCT00385502 |